心血管疾病药物治疗:从草药和药片到核酸药物
心血管疾病致残致死率高,危险因素控制不佳、依从性不理想,现有治疗不足以完全阻止动脉粥样硬化性心血管病、心衰、心律失常和瓣膜病进展。对遗传基础认识加深与治疗技术进步推动了核酸药物治疗(NATs)用于心血管危险因素和疾病的预防与治疗,可靶向翻译水平阻止致病蛋白形成,并通过长效作用改善依从性;但长期非预期副作用、特异性、靶向性和稳定性等问题以及监管审批和临床实施障碍仍需关注。
要点
- NATs可靶向翻译水平阻止其他药物难以有效靶向的致病蛋白形成。
- NATs通过数月长效作用而非每日给药,可能改善治疗依从性。
- NATs面临长期非预期副作用、特异性、靶向性和稳定性等挑战。
核心结论
- 核酸药物治疗可靶向翻译水平阻止致病蛋白形成,并可能通过长效作用改善依从性。
- NATs的挑战因新药和新靶点而异,可能包括长期非预期副作用及特异性、靶向性和稳定性问题。
- NATs上市审批面临药物性质多样、药理学及临床安全有效性数据有限、缺乏长期结果等挑战。
研究设计与样本
- 本文为Eur Heart J综述,围绕心血管疾病药物治疗从草药和药片到核酸药物的进展进行论述。
主要发现
- 现有治疗不足以完全预防动脉粥样硬化性心血管病、心衰、心律失常和瓣膜病进展。
- NATs包括RNA靶向治疗、基因编辑治疗和基因治疗。
- 临床实践障碍可能包括缺乏专门教育、对脱靶效应的担忧、成本和伦理挑战。
- 尽管治疗成本可能较高,但因NATs给药不频繁可减少就诊次数,并因疾病通路和危险因素控制持续改善而降低疾病进展、住院和心血管事件率,可能带来长期费用节省。
临床怎么用
- 实施这些新型疗法需要仔细选择患者并进行教育。
- 临床实践需关注缺乏专门教育、对脱靶效应的担忧、成本和伦理挑战等障碍。
局限性
- NATs的长期非预期副作用尚不明确。
- NATs在特异性、靶向性和稳定性方面存在问题。
- NATs上市审批缺乏药理学、临床安全有效性和长期结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular (CV) diseases continue to cause substantial morbidity and mortality. Risk factors are inadequately controlled, compliance with medication remains suboptimal, and treatments are not sufficient to fully prevent the progression of atherosclerotic CV disease, heart failure, arrhythmias, and valvular heart diseases. An increased understanding of the genetic basis of CV diseases and advances in the technology of therapeutics have led to the development of nucleic acid-based therapies (NATs) for prevention and treatment of CV risk factors and diseases. Nucleic acid-based therapies can target disease pathways at the translational level preventing the formation of disease-causing proteins that could not be effectively targeted by other pharmacological therapeutics and will likely improve treatment adherence by providing long-acting effects over many months rather than daily treatment. These therapies include RNA-targeted therapeutics, gene editing therapeutics, and gene therapies. Challenges around the use of NATs may be unique with each new drug and new target and may include long-term unanticipated side effects, and issues around specificity, targeting, and stability. Assessing NATs for marketing approval continues to pose challenges for regulatory agencies. These include their diverse nature, limited data on pharmacology, clinical safety and efficacy, and the lack of long-term results. Barriers in clinical practice may include the lack of specific education, fear of off target effects, costs, and ethical challenges. Implementation of these novel therapies will require careful patient selection and education. Despite potentially high treatment costs, possible long-term cost savings could result from fewer healthcare visits due to infrequent NAT administrations, and lower rates of disease progression, hospitalization, and CV events due to sustained improvement in control of disease pathways and risk factors.
引用
- Landmesser U, Thum T, Tokgözoğlu L, et al. Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids. Eur Heart J. 2026. PMID: 40838984. doi:10.1093/eurheartj/ehaf520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。